HHS proposed a rule Tuesday that, if enacted, would expand access to anti-obesity medications like Wegovy, Ozempic, and Mounjaro to millions of Medicare and Medicaid beneficiaries. The regulation ...
Obesity experts have said that nearly 20% patients may not respond well to GLP-1 medications. They explained that these drugs do not work on one-size-fits-all principle.